TTrialPathMatch Me to Trials
← Back to trials
RecruitingPsoriasis Vulgaris

Psoriatic Immune Response to Tildrakizumab

Eligible age

18–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Sponsor: University of California, San Francisco

You may qualify if…

  • ✓ 18 years of age or older
  • ✓ Patients with moderate-severe psoriasis or \> 5% body surface area affected.

You may not qualify if…

  • ✕ taking systemic immunosuppressives in the last 4 weeks
  • ✕ pregnancy
  • ✕ severe immunodeficiency (either from genetic or infectious causes).
  • ✕ tuberculosis or other active serious infection
  • ✕ active systemic malignancy.
  • ✕ breast-feeding
  • ✕ Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Where it's recruiting

California

San Francisco

Source: ClinicalTrials.gov · NCT05390515 · last updated 2026-06-04

Psoriatic Immune Response to Tildrakizumab · TrialPath